ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.33
1.50%
US Tech 100
19,167.20
2.31%
S&P 500
5,638.94
2.13%
US Dollar vs CAD
1.43865
0.00%
Bitcoin
84,213.06
-0.16%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Phathom Pharmaceuticals Inc (PHAT) Share Price

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc (PHAT)

NASDAQ
4.41
0.19
(4.50%)
Closed March 15 3:00PM
Delayed by 15 minutes
4.4499
0.0399
(0.90%)
After Hours: 5:25PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
4.4499
Bid
3.96
Ask
4.49
Volume
1,241,742
4.07 Day's Range 4.48
4.185 52 Week Range 19.71
Market Cap
304.272M
Previous Close
4.22
Open
4.24
Last Trade
6000
@
4.4499
(formt)
Last Trade Time
Financial Volume
US$ 5,392,251
VWAP
4.3425
Average Volume (3m)
1,093,734
Shares Outstanding
68,377,379
Dividend Yield
-
PE Ratio
-1.49
Earnings Per Share (EPS)
-2.95
Revenue
682k
Net Profit
-201.59M

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that ... Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.phathompharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Phathom Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHAT. The last closing price for Phathom Pharmaceuticals was US$4.22. Over the last year, Phathom Pharmaceuticals shares have traded in a share price range of US$ 4.185 to US$ 19.71.

Phathom Pharmaceuticals currently has 68,377,379 shares outstanding. The market capitalization of Phathom Pharmaceuticals is US$288.55 million. Phathom Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.49.

Ask ADVFN Intelligence (AI)

PHAT Latest News

More News

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
March 06 2025
PHAT (4.50%)

Form 8-K - Current report
Edgar (US Regulatory)
March 06 2025
PHAT (4.50%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
March 06 2025
PHAT (4.50%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 03 2025
PHAT (4.50%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 23 2025
PHAT (4.50%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
December 20 2024
PHAT (4.50%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
December 16 2024
PHAT (4.50%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.3201-22.87868284235.775.774.18516281214.70484704CS
4-1.5501-25.83566.984.18512126925.33540171CS
12-3.2601-42.28404669267.718.344.18510937346.19212795CS
26-13.8901-75.736641221418.3419.714.185120880710.40513747CS
52-3.5501-44.37625819.714.18596648510.96545869CS
156-9.0401-67.013343217213.4919.714.18557740010.40727171CS
260-18.7501-80.819396551723.264.544.18538671412.77976418CS

PHAT - Frequently Asked Questions (FAQ)

What is the current Phathom Pharmaceuticals share price?
The current share price of Phathom Pharmaceuticals is US$ 4.4499
How many Phathom Pharmaceuticals shares are in issue?
Phathom Pharmaceuticals has 68,377,379 shares in issue
What is the market cap of Phathom Pharmaceuticals?
The market capitalisation of Phathom Pharmaceuticals is USD 288.55M
What is the 1 year trading range for Phathom Pharmaceuticals share price?
Phathom Pharmaceuticals has traded in the range of US$ 4.185 to US$ 19.71 during the past year
What is the PE ratio of Phathom Pharmaceuticals?
The price to earnings ratio of Phathom Pharmaceuticals is -1.49
What is the cash to sales ratio of Phathom Pharmaceuticals?
The cash to sales ratio of Phathom Pharmaceuticals is 440
What is the reporting currency for Phathom Pharmaceuticals?
Phathom Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Phathom Pharmaceuticals?
The latest annual turnover of Phathom Pharmaceuticals is USD 682k
What is the latest annual profit for Phathom Pharmaceuticals?
The latest annual profit of Phathom Pharmaceuticals is USD -201.59M
What is the registered address of Phathom Pharmaceuticals?
The registered address for Phathom Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Phathom Pharmaceuticals website address?
The website address for Phathom Pharmaceuticals is www.phathompharma.com
Which industry sector does Phathom Pharmaceuticals operate in?
Phathom Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RDUSRadius Recycling Inc
US$ 27.902
(104.26%)
8.53M
BONBon Natural Life Ltd
US$ 1.40
(90.29%)
84M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 255.00
(39.80%)
222
AAOIApplied Optoelectronics Inc
US$ 22.105
(39.29%)
17.01M
GLSTUGlobal Star Acquisition Inc
US$ 2.00
(-69.23%)
421
CURRCurrenc Group Inc
US$ 2.03
(-41.33%)
1.42M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
WKSPWorksport Ltd
US$ 0.36205
(-35.45%)
4.96M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
NVDANVIDIA Corporation
US$ 121.67
(5.27%)
277.56M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 9.225
(7.64%)
160.21M

PHAT Discussion

View Posts
rolvram rolvram 3 months ago
Blackrock keeps accumulating
https://stockzoa.com/ticker/phat/ownership/blackrock/#google_vignette
👍️0
Monksdream Monksdream 6 months ago
PHAT new 52=high

👍️0
MiamiGent MiamiGent 7 months ago
PHAT Nice! Account increased 11%! Was stacked.
👍️0
MiamiGent MiamiGent 7 months ago
PHAT 28.5% Revenue beat!
👍️0
MiamiGent MiamiGent 7 months ago
PHAT Still in.
👍️0
FALCON1 FALCON1 8 months ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
MiamiGent MiamiGent 8 months ago
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
BENZINGA

Jul-19-2024 6:41 a.m. ET

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (PHAT) with a Buy and maintains $28 price target.
👍️0
MiamiGent MiamiGent 8 months ago
PHAT I'm hanging in!
👍️0
MiamiGent MiamiGent 8 months ago
BRIEF-Phathom Pharmaceuticals Announces FDA Approval Of Voquezna® (Vonoprazan) Tablets For The Relief Of Heartburn Associated With Non-Erosive Gerd In Adults
REUTERS

Jul-18-2024 8:41 a.m. ET

July 18 (Reuters) - Phathom Pharmaceuticals Inc (PHAT) :

* PHATHOM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VOQUEZNA® (VONOPRAZAN) TABLETS FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GERD IN ADULTS

* PHATHOM PHARMACEUTICALS INC (PHAT): VOQUEZNA MET ITS PRIMARY ENDPOINT IN ITS PHASE 3 PIVOTAL TRIAL Source text for Eikon: Further company coverage:
👍️0
MiamiGent MiamiGent 8 months ago
$PHAT FLE.
👍️0
MiamiGent MiamiGent 8 months ago
PHAT In @ 12.60's
👍️0
Monksdream Monksdream 10 months ago
PHAT under $10
👍️0
Monksdream Monksdream 1 year ago
PHAT 10Q due March 7
👍️0

Your Recent History

NASDAQ
PHAT
Phathom Pharmaceuticals
COIN
PDEXGBP
Polkadex
NASDAQ
FDIWX
Bmo European Fund Adviso...
NASDAQ
GYRE
Gyre Therapeutics
NASDAQ
NVTR
Nuvectra
NYSE
PCLO
Virtus ETF Trust
NASDAQ
FCLYX
Bmg Bullionfund Class A ...
BOV
FR0T5L
Frota Oceanica E Amazonica PNA
NASDAQ
NBSC
New Brunswick Scientific
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads